======= ASXL3 =======
== Gene Information ==
* **Official Symbol**: ASXL3
* **Official Name**: ASXL transcriptional regulator 3
* **Aliases and Previous Symbols**: N/A
* **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=80816|80816]]
* **UniProt**: [[https://www.uniprot.org/uniprot/Q9C0F0|Q9C0F0]]
* **Interactions**: [[https://thebiogrid.org/search.php?search=ASXL3&organism=9606|BioGRID]]
* **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20ASXL3|Open PubMed]]
* **OMIM**: [[https://omim.org/entry/615115|Open OMIM]]
== Function Summary ==
* **Entrez Summary**: This gene encodes a protein containing a plant homeodomain (PHD) zinc finger domain that plays a role in the regulation of gene transcription. The encoded protein has been shown to negatively regulate lipogenesis by binding to and inhibiting the transcriptional activity of two nuclear hormone receptors, oxysterols receptor LXR-alpha (LXRalpha) and thyroid hormone receptor beta (TRbeta). The encoded protein may also inhibit histone deubiquitination. Mutations in this gene have been identified in human patients with Bainbridge-Ropers syndrome, which is characterized by feeding difficulties, developmental delay and other features. [provided by RefSeq, May 2017].
* **UniProt Summary**: Putative Polycomb group (PcG) protein. PcG proteins act by forming multiprotein complexes, which are required to maintain the transcriptionally repressive state of homeotic genes throughout development. PcG proteins are not required to initiate repression, but to maintain it during later stages of development. They probably act via methylation of histones, rendering chromatin heritably changed in its expressibility (By similarity). {ECO:0000250}.
No Pfam Domain information is available for this gene.
|PR-DUB complex|
|peroxisome proliferator activated receptor binding|
|nuclear chromatin|
|chromatin binding|
|transcription, DNA-templated|
|nucleic acid-templated transcription|
|RNA biosynthetic process|
|animal organ morphogenesis|
|nucleobase-containing compound biosynthetic process|
|heterocycle biosynthetic process|
|aromatic compound biosynthetic process|
|positive regulation of transcription by RNA polymerase II|
|organic cyclic compound biosynthetic process|
|DNA binding|
|positive regulation of transcription, DNA-templated|
|cellular nitrogen compound biosynthetic process|
|positive regulation of nucleic acid-templated transcription|
|positive regulation of RNA biosynthetic process|
|RNA metabolic process|
|cellular macromolecule biosynthetic process|
|positive regulation of RNA metabolic process|
|macromolecule biosynthetic process|
|positive regulation of nucleobase-containing compound metabolic process|
|positive regulation of macromolecule biosynthetic process|
|positive regulation of cellular biosynthetic process|
|positive regulation of gene expression|
|gene expression|
|positive regulation of biosynthetic process|
\\
=== CRISPR Data ===
^Screen^Score^
|[[:results:exp476|Dihydrosphingosine 8μM R08 exp476]]|-1.87|
|[[:results:exp13|Chloramphenicol 20μM R00 exp13]]|1.7|
|[[:results:exp227|Cryptotanshinone 12μM R05 exp227]]|1.92|
|[[:results:exp282|Fluvastatin 2.2μM R06 exp282]]|2.5|
^Gene^Correlation^
|[[:human genes:r:rrm1|RRM1]]|0.418|
Global Fraction of Cell Lines Where Essential: 0/739
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|0/1|
|909776.0|0/1|
|bile duct|0/28|
|blood|0/28|
|bone|0/26|
|breast|0/33|
|central nervous system|0/56|
|cervix|0/4|
|colorectal|0/17|
|esophagus|0/13|
|fibroblast|0/1|
|gastric|0/16|
|kidney|0/21|
|liver|0/20|
|lung|0/75|
|lymphocyte|0/16|
|ovary|0/26|
|pancreas|0/24|
|peripheral nervous system|0/16|
|plasma cell|0/15|
|prostate|0/1|
|skin|0/24|
|soft tissue|0/9|
|thyroid|0/2|
|upper aerodigestive|0/22|
|urinary tract|0/29|
|uterus|0/5|
== Essentiality in NALM6 ==
* **Essentiality Rank**: 14396
* **Expression level (log2 read counts)**: -3.9
{{:chemogenomics:nalm6 dist.png?nolink |}}